Price data is not available
Monopar Therapeutics Inc (MNPR) Stock Price, Quote, News & History
MNPRNASDAQ
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. STUB downgraded, MNPR neutral, BETR.
You can purchase shares of Monopar Therapeutics (NASDAQ:MNPR) through any online brokerage.
Other companies in Monopar Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Monopar Therapeutics has a consensus price target of $97.53.
The stock price for Monopar Therapeutics (NASDAQ: MNPR) is $72.02 last updated October 29, 2026 at 9:27 AM EDT.
There are no upcoming dividends for Monopar Therapeutics.
Monopar Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Monopar Therapeutics.
Monopar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily,...
